Terminology Service for NFDI4Health
All terms in BAO
| Label | Id | Description |
|---|---|---|
| radiolabeled | BAO_0000036 | |
| assay method component | BAO_0002753 | |
| Kd | BAO_0000034 | [Kd – is the equilibrium dissociation constant for a drug. It describes the affinity between a ligand (L) (such as a drug) and a protein (P). Ligand-protein affinities are influenced by non-covalent intermolecular interactions between the two molecules such as hydrogen bonding, electrostatic interactions, hydrophobic and Van der Waals forces. Kd = ([P] [L]) / [PL] The dissociation constant has molar units (M), which corresponds to the concentration of ligand [L] at which the binding site on a particular protein is half occupied, i.e. the concentration of ligand, at which the concentration of protein with ligand bound [PL], equals the concentration of protein with no ligand bound [P]. The smaller the dissociation constant, the more tightly bound the ligand is, or the higher the affinity between ligand and protein. http://www.graphpad.com/curvefit/law_of_mass_action.htm ] |
| Bmax | BAO_0000033 | [It is the amount of drug required to saturate a population of receptors and a measure of the number of receptors present in the sample. It is derived from Scatchard plot of binding data. It is analogous to Vmax in enzyme kinetics. The units of Bmax include cpm, sites/cell or fmol/mg. http://graphpad.com/curvefit/fitting_specific_binding_.htm] |
| secondary assay | BAO_0000032 | [Additional assays following the confirmatory stage to confirm the biological activity of chemical entities via a different type of assay or to eliminate certain active compounds based on their mechanism of action, toxicity or activity profile. Secondary assays can also include selectivity and specificity assays.] |
| primary assay | BAO_0000031 | [The first assay performed in a in a screening campaign. The purpose of the primary assay is to identify hits, which are potentially biologically active chemical entities. Generally in this assay, the perturbagens are tested at a single concentration with only one measurement. It is followed by a confirmatory screen, which can be run at a single concentration with multiple replicates or as concentration-response assay.] |
| confirmatory assay | BAO_0000030 | [Assay performed to confirm activity of compounds identified in the primary screen. It can be performed as replicate measurements at a single screening concentration or as concentration-response assay.] |
| LYMP2-021 | BAO_0002691 | |
| LYMP2-019 | BAO_0002692 | |
| LYMP2-017 | BAO_0002693 | |
| RBL-2H3 | BAO_0002694 | |
| time unit | UO_0000003 | [A unit which is a standard measure of the dimension in which events occur in sequence.] |
| LYMP2-013 | BAO_0002695 | |
| LYMP2-011 | BAO_0002696 | |
| length unit | UO_0000001 | [A unit which is a standard measure of the distance between two points.] |
| unlabeled | BAO_0000038 | |
| LYMP2-009 | BAO_0002697 | |
| LYMP2-005 | BAO_0002698 | |
| capillary leak syndrome | DOID_14400 | |
| capillary disease | DOID_1271 | [A vascular disease that is located_in the capillaries.] |